Bicycle Therapeutics Limited Stock Price, News & Analysis

BioMed Realty has successfully leased 96,000 square feet at the renovated Portway building in Cambridge, with Bicycle Therapeutics occupying 45,000 sq. ft. and Altos Labs taking 51,000 sq. ft. Both leases span 10 years, amid a notable shortage of life sciences space in the area, where availability has dipped to 2.2%. The Portway building is notable for its WELL certification and WiredScore Gold certification, ensuring exceptional health and connectivity standards.

Bicycle Therapeutics (NASDAQ: BCYC) reported financial results for Q4 and full-year 2021, highlighting progress in its oncology pipeline. Key updates include the ongoing Phase I/II trials for BT8009 and BT5528, which have shown promising anti-tumor activity. Cash reserves reached $438.7 million as of December 31, 2021, projected to fund operations through 2024. The company also announced management transitions and presented preclinical data for BT7480. However, the company reported a net loss of $66.8 million for the year.

Bicycle Therapeutics plc (NASDAQ: BCYC), a pioneering biopharmaceutical company, announced participation in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 9:20 a.m. ET. The virtual event will be accessible on Bicycle's website, with an archived playback available for 90 days post-event. The company specializes in developing innovative therapeutics called Bicycles, which are being evaluated in multiple Phase I/II trials, targeting various cancer-related antigens.

Bicycle Therapeutics plc (NASDAQ: BCYC) announced progress in its Phase I/II clinical trials of BT8009, BT5528, and BT7480. Interim results show ongoing anti-tumor activity in patients treated with BT8009, with four confirmed partial responses, including one complete response. The company is set to present further interim results at a medical meeting this year. Management changes include the appointment of Michael Skynner as CTO and Alistair Milnes as COO, aimed at accelerating growth in their oncology pipeline.

Bicycle Therapeutics plc (NASDAQ: BCYC) announced participation in several investor conferences during November and December 2021. These include the Jefferies London Healthcare Conference on November 19, Piper Sandler's Healthcare Conference on December 2, JMP Securities Hematology & Oncology Summit on December 6, and Jefferies Denver Healthcare Summit on December 15. Pre-recorded fireside chats will be available before each event, with webcasts accessible on the company’s website for 30 days following the chats.

Bicycle Therapeutics (NASDAQ: BCYC) announced the presentation of preclinical data for its novel tumor-targeted immune cell agonists BT7480 and BT7455 at the Society for Immunotherapy of Cancer's 36th Annual Meeting from November 10-14, 2021. The preclinical results support the initiation of a Phase I/II trial for BT7480, indicating potential anti-tumor responses in syngeneic mouse models. The data also formed the basis for a pharmacokinetic/pharmacodynamic modeling framework to optimize dosing schedules. These developments position Bicycle Therapeutics favorably in the competitive biotechnology landscape.

Bicycle Therapeutics (NASDAQ: BCYC) reported interim Phase I results for its BT5528 and BT8009 clinical trials, indicating preliminary anti-tumor activity. Cash reserves were $259.5 million as of September 30, 2021, boosted by recent financing activities. The firm also dosed the first patient in the BT7480 Phase I/II trial, targeting advanced solid tumors. Genentech expanded its collaboration with Bicycle, triggering a $10 million payment. The company experienced an increased net loss of $14.7 million, reflecting higher R&D and administrative expenses.

Bicycle Therapeutics (NASDAQ: BCYC) announced the first patient has been dosed in a Phase I/II trial for BT7480, a novel tumor-targeted immune cell agonist targeting Nectin-4, which aims to enhance anti-tumor immunity. This marks Bicycle's first entry into immuno-oncology and its fourth product candidate in clinical development within four years. The trial will primarily assess the safety and tolerability of BT7480, which has shown encouraging preclinical results. Future trials may include combinations with nivolumab.

Bicycle Therapeutics (NASDAQ: BCYC) announced a publication in the Journal for ImmunoTherapy of Cancer featuring preclinical data on BT7480, a tumor-targeted immune cell agonist. This innovative therapy targets Nectin-4 and activates CD137 selectively in tumor environments, enhancing anti-tumor immunity with intermittent use. The findings reveal BT7480’s capability to rapidly alter the tumor immune microenvironment, leading to complete regressions in mouse models. Bicycle aims to commence a Phase I/II clinical trial by year's end, furthering its commitment to cancer treatment innovation.